Sarcoma Trials Offer Blueprint for Rarer Cancers Under New WHO and Global Trial Rules
A new review in eClinicalMedicine shows how sarcoma trials can guide the implementation of the 2024 WHO guidance and ICH ...
A new review in eClinicalMedicine shows how sarcoma trials can guide the implementation of the 2024 WHO guidance and ICH ...
A 23-year New Zealand population study found that oestrogen receptor testing and endocrine therapy for DCIS remained rare nationally, driven ...
A new commentary argues that exceptional long-term responses to melflufen-dexamethasone in myeloma case reports should not override subgroup trial evidence ...
A new review documents how the Czech Republic has built a long phage therapy tradition into modern academic, industrial, and ...
A systematic review and meta-analysis of 70 clinical studies finds that newer BTK inhibitors acalabrutinib and zanubrutinib outperform ibrutinib as ...
A new interview study finds that scientists broadly promote epigenetic editing as a safer alternative to gene editing while privately ...
A national expert convening argues that primary care, which handles over half of US outpatient visits but receives under 1% ...
A new Gene Therapy review charts how mutation-agnostic optogenetic gene therapy could restore vision in blind patients, while detailing the ...
A comprehensive new guideline synthesizes the full landscape of anti-cancer drug clinical research, from preclinical requirements and trial phases to ...
Pomalidomide (POM) has emerged as a pivotal agent in the treatment landscape for multiple myeloma, a malignancy that significantly compromises ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine